GLP-1 receptor agonist

Semaglutide

The Ozempic label gives semaglutide's elimination half-life as approximately 1 week; the app lists 161 hours, about 6.7 days.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Semaglutide after one dose: 50% at ~161 h, 25% at 322 h, 12.5% at 483 h.

Drawn from the half-life in the app's model, ~161 h. The model's figures

Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk and sold in the United States as Ozempic and Wegovy.1,2 The Ozempic label lists three uses in adults with type 2 diabetes mellitus: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.1 The Wegovy injection label lists, in combination with a reduced calorie diet and increased physical activity, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight and a weight-related comorbid condition; and, under accelerated approval, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults.2 The same Wegovy label also covers a once-daily tablet; the app's figures here are for the subcutaneous route it lists.2

The European Medicines Agency's product information for Ozempic gives 08 February 2018 as the date of first authorisation, and both US labels give 2017 as the initial approval year.3,1,2 The app grades the evidence for semaglutide as strong, and the trials described below were funded by Novo Nordisk, apart from SURMOUNT-5, which Eli Lilly funded.

2

How it works

The Ozempic label describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1 that acts as a GLP-1 receptor agonist.1 It states that "the principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation", and that semaglutide "stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner".1

Lau and colleagues, whose affiliations are all given as Global Research, Novo Nordisk, described the design of semaglutide in the Journal of Medicinal Chemistry in 2015.4 They report that it "has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26".4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~161 h
Bioavailability
89%
Typical dose
0.25–2.4 mg/week
Route
SubQ
Time to peak
~48 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 6.7 days (161 hours)Elimination half-life of approximately 1 week on the Ozempic and Wegovy labels and in the European product information; geometric mean terminal half-lives of 145, 163, 159 and 167 hours in four groups of 6 to 8 healthy men at steady state in a Novo Nordisk-funded trial on 0.5 or 1.0 mg once weekly (Japanese 0.5 mg, Japanese 1.0 mg, Caucasian 0.5 mg, Caucasian 1.0 mg)1,2,3,5
Bioavailability89% by subcutaneous injectionAbsolute bioavailability of 89% on the Ozempic label, 89% following subcutaneous administration on the Wegovy label, and 89% in the European product information1,2,3
Time to peakAbout 48 hoursMaximum concentration reached 1 to 3 days post dose on the Ozempic and Wegovy labels and in the European product information; median time to maximum concentration at steady state of 30, 36, 36 and 30 hours (ranges within 12 to 96 hours) in the same four groups of healthy men1,2,3,5
Steady stateAbout 4 to 5 weeksSteady-state exposure after 4 to 5 weeks of once-weekly administration on the Ozempic label and in the European product information1,3
Volume of distributionAbout 12.5 L (apparent)Approximately 12.5 L (apparent, in type 2 diabetes) on the Ozempic label and approximately 12.5 L (in obesity or overweight) on the Wegovy label; steady-state Vz/F geometric means of 7.11, 7.69, 8.25 and 7.84 L in the four groups of healthy men1,2,5

The Ozempic label gives an apparent clearance of approximately 0.05 L/h in type 2 diabetes, against steady-state CL/F geometric means of 0.034, 0.033, 0.036 and 0.032 L/h in the four groups of healthy men, a different population.1,5 The Wegovy label states that semaglutide is extensively bound to plasma albumin (greater than 99%).2

Jensen and colleagues gave a single 0.5 mg subcutaneous dose of radiolabelled semaglutide to healthy human subjects (European Journal of Pharmaceutical Sciences, 2017); seven of the nine listed authors are at Novo Nordisk, the other two at PRA Health Sciences, and the record holds no funding statement.6 They report that intact semaglutide was "the primary component circulating in plasma" across humans and two nonclinical species, accounting for 69-83% of the semaglutide-related material.6

The chart draws the app's one-compartment model with its half-life of 161 hours and time to peak of 48 hours, an illustration and not a measured level.

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 1 mg dose

As studied: every 7 days (once weekly)1.

An illustration from a pharmacokinetic model using a half-life of 161 hours (6.71 days). It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Wilding and colleagues, STEP 1, New England Journal of Medicine 20217Double-blind trial; funded by Novo Nordisk71961 adults with a BMI of 30 or greater (27 or greater with a weight-related coexisting condition), without diabetes7Semaglutide 2.4 mg or placebo once weekly, plus lifestyle intervention, assigned 2:1; 68 weeks7Weight change to week 68 of -14.9% with semaglutide against -2.4% with placebo (difference -12.4 percentage points, 95% CI -13.4 to -11.5; P<0.001); discontinuation for gastrointestinal events in 59 (4.5%) against 5 (0.8%)7
Rubino and colleagues, STEP 4, JAMA 20218Randomised, double-blind withdrawal study; funded by Novo Nordisk, whose representatives took part in its design, conduct, analysis and manuscript; three listed authors at Novo Nordisk, and the first author a Novo Nordisk shareholder8803 adults, without diabetes, who reached the 2.4 mg dose in a 20-week run-in of 9028Continued semaglutide 2.4 mg (n=535) or a switch to placebo (n=268), once weekly, for 48 weeks after the 20-week run-in8Weight change from week 20 to week 68 of -7.9% with continued semaglutide against +6.9% with the switch to placebo (difference -14.8 percentage points, 95% CI -16.0 to -13.5; P<.001); gastrointestinal events in 49.1% against 26.1%; discontinuation because of adverse events in 2.4% against 2.2%8
Aronne and colleagues, SURMOUNT-5, New England Journal of Medicine 20259Phase 3b open-label trial against tirzepatide; funded by Eli Lilly, with seven listed authors at Eli Lilly9751 adults with obesity but without type 2 diabetes9Maximum tolerated dose of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg), once weekly; 72 weeks9Weight change at week 72 of -13.7% with semaglutide (95% CI -14.9 to -12.6) against -20.2% with tirzepatide (P<0.001); the most common adverse events in both groups were gastrointestinal, mostly mild to moderate and mainly during dose escalation9
Marso and colleagues, SUSTAIN-6, New England Journal of Medicine 201610Randomised, placebo-controlled noninferiority trial; funded by Novo Nordisk103297 adults with type 2 diabetes on standard care; 2735 (83.0%) had established cardiovascular disease, chronic kidney disease, or both10Semaglutide 0.5 mg or 1.0 mg, or placebo, once weekly; 104 weeks10Cardiovascular death, nonfatal myocardial infarction or nonfatal stroke in 108 of 1648 (6.6%) against 146 of 1649 (8.9%) (hazard ratio 0.74, 95% CI 0.58 to 0.95; P<0.001 for noninferiority); retinopathy complications higher with semaglutide (hazard ratio 1.76, 95% CI 1.11 to 2.78)10
Lincoff and colleagues, SELECT, New England Journal of Medicine 202311Multicenter, double-blind, randomised, placebo-controlled superiority trial; funded by Novo Nordisk1117,604 patients aged 45 or older with preexisting cardiovascular disease and a BMI of 27 or greater, without a history of diabetes11Semaglutide 2.4 mg or placebo once weekly; mean exposure 34.2 months, mean follow-up 39.8 months11Cardiovascular death, nonfatal myocardial infarction or nonfatal stroke in 569 of 8803 (6.5%) against 701 of 8801 (8.0%) (hazard ratio 0.80, 95% CI 0.72 to 0.90; P<0.001); adverse events leading to permanent discontinuation in 1461 (16.6%) against 718 (8.2%)11
Perkovic and colleagues, FLOW, New England Journal of Medicine 202412Randomised, placebo-controlled trial, with early cessation recommended at a prespecified interim analysis; funded by Novo Nordisk123533 adults with type 2 diabetes and chronic kidney disease, defined by estimated glomerular filtration rate and urinary albumin-to-creatinine ratio12Semaglutide 1.0 mg or placebo once weekly; median follow-up 3.4 years12Major kidney disease events in 331 against 410 (hazard ratio 0.76, 95% CI 0.66 to 0.88; P = 0.0003); death from any cause, hazard ratio 0.80 (95% CI 0.67 to 0.95); serious adverse events in 49.6% against 53.8%12

For STEP 1, SUSTAIN-6, SELECT and FLOW, the text read holds the summary results, author affiliations and registry entries but not the full papers, so their own limitation and disclosure statements are not given below.7,10,11,12

Deeper analysis: STEP 1

Wilding and colleagues reported STEP 1 in the New England Journal of Medicine in 2021, and the affiliation list places three authors (S.C., M.T.D.T. and N.Z.) at Novo Nordisk, Søborg, Denmark.7 The primary estimand "assessed effects regardless of treatment discontinuation or rescue interventions".7 More participants on semaglutide than on placebo reached weight reductions of 10% or more (838 [69.1%] against 69 [12.0%]) and 15% or more (612 [50.5%] against 28 [4.9%]) at week 68.7 The authors write that nausea and diarrhea "were typically transient and mild-to-moderate in severity and subsided with time".7 The registry entry names Novo Nordisk A/S as lead sponsor, posts a treatment-policy estimand difference of -12.44 (95% CI -13.37 to -11.51) and a hypothetical estimand difference of -14.42, and lists one death among 1306 participants on semaglutide and one among 655 on placebo, with serious adverse events in 128 and 42.13

An off-treatment extension (Wilding and colleagues, Diabetes, Obesity and Metabolism, 2022) assessed what its authors call a representative subset of 327 participants who had completed 68 weeks of treatment, for a further year after treatment stopped, with all analyses exploratory.14 In that set, observed weight loss to week 68 was 17.3% with semaglutide and 2.0% with placebo, slightly greater than in the full trial population, which the authors attribute to including only participants who completed 68 weeks of treatment.14 The groups regained 11.6 and 1.9 percentage points by week 120, and net losses at week 120 were 5.6% and 0.1%.14 The authors name "the relatively small sample size compared with the main STEP 1 trial population and the selection of sites based on those with the highest recruitment" as key limitations of the extension, which "could introduce an element of selection bias".14 Its methods state that "No systematic collection of adverse events was performed in the extension".14

Deeper analysis: SUSTAIN-6

Marso and colleagues reported SUSTAIN-6 in the New England Journal of Medicine in 2016, and three authors (O.H., A.G.H. and J.P.) are listed at Novo Nordisk, Søborg.10 The authors hypothesised that semaglutide would be noninferior to placebo, with a margin of 1.8 for the upper boundary of the hazard ratio's confidence interval.10 Nonfatal myocardial infarction occurred in 2.9% against 3.9% (hazard ratio 0.74, 95% CI 0.51 to 1.08; P=0.12) and nonfatal stroke in 1.6% against 2.7% (hazard ratio 0.61, 95% CI 0.38 to 0.99; P=0.04), and "rates of death from cardiovascular causes were similar in the two groups".10 The Ozempic label gives diabetic retinopathy complications in a 2-year trial in type 2 diabetes with high cardiovascular risk as 3.0% against 1.8%, and as 8.2% against 5.2% among patients with a history of diabetic retinopathy at baseline and 0.7% against 0.4% among those without.1 The authors report "fewer serious adverse events" with semaglutide, "although more patients discontinued treatment because of adverse events, mainly gastrointestinal".10 The registry entry names Novo Nordisk A/S as lead sponsor.15

Deeper analysis: SELECT

Lincoff and colleagues reported SELECT in the New England Journal of Medicine in 2023, and seven authors (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M. and C.W.T.) are listed at Novo Nordisk, Søborg, Denmark.11 The Wegovy label reports a median follow-up of 41.8 months, permanent discontinuation of study drug in 31% against 27%, and cardiovascular death in 223 (2.5%) against 262 (3%) (hazard ratio 0.85, 95% CI 0.71 to 1.01), for which "superiority was not confirmed".2 It reports all-cause death in 375 (4.3%) against 458 (5.2%) (hazard ratio 0.81, 95% CI 0.71 to 0.93), described as "Not statistically significant based on the prespecified testing hierarchy".2 For hospitalization for heart failure or urgent heart failure visits it reports 97 (1.1%) on semaglutide against 122 (1.4%) on placebo (hazard ratio 0.79, 95% CI 0.6 to 1.03), a row that was "Not included in the prespecified testing hierarchy for controlling type-I error" and carries the footnote "Effect on heart failure has not been established".2 The registry entry names Novo Nordisk A/S as lead sponsor.16

Deeper analysis: FLOW

Perkovic and colleagues reported FLOW in the New England Journal of Medicine in 2024, and four authors (F.M.M.B., T.I., H.B.-T. and N.L.L.) are listed at Novo Nordisk, Søborg.12 The primary outcome was major kidney disease events, a composite of kidney failure, at least a 50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes.12 The mean annual eGFR slope was less steep by 1.16 ml per minute per 1.73 m2 with semaglutide, and the risk of major cardiovascular events was 18% lower (hazard ratio 0.82, 95% CI 0.68 to 0.98; P = 0.029).12 The Ozempic label states that "the treatment benefit on the primary composite endpoint was not evident in patients taking SGLT2 inhibitors at baseline, but there were few events in these patients".1 The registry entry names Novo Nordisk A/S as lead sponsor and lists deaths in 227 of 1767 participants on semaglutide and 279 of 1766 on placebo, with serious adverse events in 877 and 950.17

5

Doses reported in studies and on labels

The app's typical dose of 0.25 to 2.4 mg per week runs from the labels' starting dosage to the Wegovy label's 2.4 mg maintenance dosage, listed as "either 1.7 mg or 2.4 mg (recommended)"; the Ozempic label's maximum is 2 mg once weekly, and the Wegovy injection label allows a maximum of 7.2 mg once weekly for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated.1,2

Table 5.1Doses reported in studies and on labels2 rows
SourcePopulationDose reportedSchedule and length
Ozempic US label1Adults with type 2 diabetes mellitus1Starting dosage 0.25 mg for 4 weeks, then 0.5 mg; maintenance 0.5, 1 or 2 mg, with increases after at least 4 weeks on the current dosage if additional glycemic control is needed; maximum 2 mg; with chronic kidney disease, 1 mg after at least 4 weeks on 0.5 mg1Subcutaneous, once weekly1
Wegovy US label, injection2Adults, and pediatric patients aged 12 years and older20.25 mg in weeks 1 through 4, 0.5 mg in weeks 5 through 8, 1 mg in weeks 9 through 12 and 1.7 mg in weeks 13 through 16; maintenance for weight reduction in adults of 1.7 mg or 2.4 mg (recommended), with an increase to a maximum of 7.2 mg for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated; in pediatric patients, maintenance of 2.4 mg (recommended) or 1.7 mg2Subcutaneous, once weekly2
6

Side effects reported

The Wegovy label pools three randomized, double-blind, placebo-controlled trials of 2,116 adults with obesity or overweight treated with 2.4 mg for up to 68 weeks, with a 7-week off-drug follow-up; 6.8% on semaglutide and 3.2% on placebo permanently discontinued because of adverse reactions, most often for nausea (1.8% against 0.2%), vomiting (1.2% against 0%) and diarrhea (0.7% against 0.1%).2

Table 6.1Side effects reported7 rows
Adverse reactionPlacebo (N=1,261)Wegovy 2.4 mg (N=2,116)
Nausea216%244%2
Diarrhea216%230%2
Vomiting26%224%2
Constipation211%224%2
Abdominal pain210%220%2
Headache210%214%2
Hair loss21%23%2

The table lists seven of the label's adverse reactions reported in 2% or more of adults on 2.4 mg and more often than on placebo.2 In the Ozempic label's pool of two placebo-controlled trials in type 2 diabetes (260 on 0.5 mg, 261 on 1 mg, 262 on placebo), nausea occurred in 15.8% and 20.3% against 6.1%, vomiting in 5% and 9.2% against 2.3%, and diarrhea in 8.5% and 8.8% against 1.9%.1

In the two 72-week trials of the 7.2 mg injection (1,311 on 7.2 mg, 304 on 2.4 mg, 303 on placebo), dysesthesia was reported by 22% on 7.2 mg, 6% on 2.4 mg and 0% on placebo, and permanent discontinuation because of adverse reactions occurred in 5%, 5% and 2%.2

The Ozempic boxed warning states that "it is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" and that semaglutide causes thyroid C-cell tumors in rodents.1 Both labels contraindicate it in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2.1,2 The Wegovy label's other warnings cover acute pancreatitis, acute gallbladder disease, hypoglycemia with insulin or an insulin secretagogue, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase and pulmonary aspiration during general anesthesia or deep sedation.2

The app lists blood glucose, HbA1c and body weight as markers. Percentage change in body weight was a coprimary end point of STEP 1, and in the Wegovy label's Study 2 (NCT03548935, listed in the registry as STEP 1) HbA1c changed by -0.4 percentage points with semaglutide against -0.2 with placebo from a baseline of 5.7, a difference of -0.3.7,2,13 In its Study 3 (type 2 diabetes with obesity or overweight) HbA1c changed by -1.6 against -0.4 from a baseline of 8.1, a difference of -1.2; the label notes that these parameters were "Not included in the pre-specified hierarchical testing (except HbA 1c for Study 3)".2

8

Regulatory and anti-doping status

FDA's page on unapproved GLP-1 drugs, current as of 1 October 2026, states that unapproved versions of drugs including semaglutide "do not undergo FDA's review for safety, effectiveness and quality before they are marketed".18 It states that as of May 31, 2026 FDA had received 990 reports of adverse events associated with compounded semaglutide, that "it is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed", and that it is likely adverse events from compounded versions "are underreported".18 A search of the text of the World Anti-Doping Agency's 2026 Prohibited List found no entry for semaglutide; its class S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and its class S2 (peptide hormones, growth factors, related substances and mimetics) states that "The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited".19 The list text does not state whether semaglutide falls under that wording.19

9

Storage and handling

The Ozempic label states that, before first use, the pen is stored in a refrigerator between 2°C to 8°C (36°F to 46°F), and that after first use it can be stored for 56 days at 15°C to 30°C or in a refrigerator, and must not be frozen.1 For the Ozempic single-dose prefilled syringes, the label states refrigeration at 2°C to 8°C (36°F to 46°F), with 8°C to 30°C (46°F to 86°F) for up to 28 days if needed.1 The label lists Ozempic pens at 0.68, 1.34 and 2.68 mg/mL, and the Wegovy label lists single-dose pens from 0.25 mg/0.5 mL to 7.2 mg/0.75 mL and a FlexTouch pen of 9.6 mg/3 mL (3.2 mg/mL).1,2

The Ozempic label states that the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.1 The Wegovy label states that "the exact mechanism of semaglutide in CV risk reduction in adults has not been established".2 Its pregnancy Risk Summary opens "Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy", states that pharmacovigilance and trial data are "insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes", and adds that "Weight loss offers no benefit to a pregnant patient and may cause fetal harm".2 Both US labels and the European product information give at least 2 months before a planned pregnancy as the point of discontinuation, citing the long half-life or washout period.1,2,3 SURMOUNT-5, the trial against another drug in the table, was open-label and enrolled adults without type 2 diabetes.9

What is the half-life of semaglutide?

The Ozempic label gives semaglutide's elimination half-life as approximately 1 week, and the app lists about 6.7 days (161 hours).1 A trial of healthy men reported geometric mean terminal half-lives of 145 to 167 hours across four groups.5

How long does semaglutide take to reach its peak level?

The labels give the time to maximum concentration as 1 to 3 days post dose, and the app lists about 48 hours.1 The same trial of healthy men reported median times to maximum concentration of 30 to 36 hours at steady state.5

What is the bioavailability of semaglutide?

The Ozempic label gives an absolute bioavailability of 89%, which equals the app's figure.1

How long does semaglutide take to reach steady state?

The Ozempic label states that steady-state exposure is achieved following 4 to 5 weeks of once-weekly administration.1

How much weight did people lose on semaglutide in trials?

In STEP 1, funded by Novo Nordisk, the mean weight change at week 68 was -14.9% with semaglutide 2.4 mg against -2.4% with placebo, in 1961 adults without diabetes, with a lifestyle intervention in both groups.7 In STEP 4, also funded by Novo Nordisk, the 803 randomised participants had lost a mean of 10.6% in the 20-week run-in, and from week 20 to week 68 weight changed by +6.9% in the 268 randomised to switch to placebo and by -7.9% in the 535 randomised to continue semaglutide.8

How does semaglutide compare with tirzepatide in trials?

In SURMOUNT-5, an open-label trial in 751 adults with obesity, the weight change at week 72 was -13.7% with semaglutide and -20.2% with tirzepatide (P<0.001).9 Eli Lilly, which makes tirzepatide, funded the trial.9

What are the side effects of semaglutide?

In the Wegovy label's pooled placebo-controlled trials, nausea occurred in 44% of adults on 2.4 mg against 16% on placebo, and diarrhea in 30% against 16%.2 The boxed warning concerns thyroid C-cell tumors in rodents, with the human relevance not determined.1

Is semaglutide FDA approved?

Yes, as Ozempic and Wegovy; both US labels give 2017 as the initial approval year.1,2 FDA's page on unapproved GLP-1 drugs states that compounded drugs are not FDA approved.18

Is semaglutide banned by WADA?

The text of the World Anti-Doping Agency's 2026 Prohibited List does not name semaglutide.19 Its class S2 also prohibits "other substances with similar chemical structure or similar biological effect(s)" to those it names, and the list text does not state whether semaglutide falls under that wording.19

13

References

  1. Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. US prescribing information, DailyMed record published 10 June 2026. DailyMed label
  2. Novo Nordisk. Wegovy (semaglutide) injection and tablets. US prescribing information, DailyMed record published 30 June 2026. DailyMed label
  3. European Medicines Agency. Ozempic: summary of product characteristics (EPAR product information). EMA product information
  4. Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem 2015. PMID 26308095
  5. Ikushima I, et al. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Adv Ther 2018. PMC5910468
  6. Jensen L, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci 2017. PMID 28323117
  7. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021. PMID 33567185
  8. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021. PMC7988425
  9. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025. PMID 40353578
  10. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016. PMID 27633186
  11. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023. PMID 37952131
  12. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024. PMID 38785209
  13. ClinicalTrials.gov. NCT03548935: STEP 1, semaglutide in people with overweight or obesity. Registry entry with posted results, record last updated 19 November 2021. NCT03548935
  14. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022. PMC9542252
  15. ClinicalTrials.gov. NCT01720446: SUSTAIN 6, cardiovascular and other long-term outcomes with semaglutide in type 2 diabetes. Registry entry with posted results, record last updated 27 June 2019. NCT01720446
  16. ClinicalTrials.gov. NCT03574597: SELECT, semaglutide effects on heart disease and stroke in patients with overweight or obesity. Registry entry, record last updated 30 August 2024. NCT03574597
  17. ClinicalTrials.gov. NCT03819153: FLOW, semaglutide compared to placebo in people with type 2 diabetes and chronic kidney disease. Registry entry with posted results, record last updated 20 March 2025. NCT03819153
  18. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 1 October 2026. FDA page
  19. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list